Brii Biosciences Limited
OTC: BRIBF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Zhi Hong
- Employees
- 98
- Headquarters
- Beijing, China
- IPO year
- 2022
- Market cap
- $107.8M
- Website
- https://www.briibio.com
Loading BRIBF…
Loading profile data…Frequently asked questions about BRIBF
What does Brii Biosciences Limited (BRIBF) do?
Brii Biosciences Limited, established in 2017 and headquartered in Beijing, China, is dedicated to advancing therapeutic solutions for infectious diseases and disorders affecting the central nervous system. Their diverse pipeline includes BRII-778 and BRII-732, both progressing through Phase I clinical trials for HIV patients. For Hepatitis B (H...
Where does BRIBF trade?
Brii Biosciences Limited (BRIBF) trades on the Other OTC.
What sector is BRIBF in?
Brii Biosciences Limited (BRIBF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Brii Biosciences Limited?
Zhi Hong is the chief executive officer of Brii Biosciences Limited (BRIBF).
Where is Brii Biosciences Limited headquartered?
Brii Biosciences Limited is headquartered in China.
Does BRIBF pay a dividend?
Brii Biosciences Limited (BRIBF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BRIBF go public?
Brii Biosciences Limited (BRIBF) completed its initial public offering in 2022.